Stifel began coverage on 10 rare disease-focused companies, with seven “buy” and three “hold” ratings, noting that with an estimated 7,000-plus rare diseases – 95% of which lack approved therapy – these are early...
Tag - AGTC
Copyright © 2024 BioTuesday Publishing Corporation - Privacy Policy